



Certificate

Quality Assessment Report QV 1530-220315, Myopathies I/2022 "Antibodies in autoimmune myopathies"

Dr. Ivana Půtová, Institute of the Rheumatology, Laboratory of the Immunology, has participated in above stated Quality Assessment of our Institute and has **fulfilled** the requirements for the following analytic parameters:

| Parameter | Ig class | Method |
|----------------|----------|-----------------|
| anti-cN-1A | IgG | ELISA*** |
| anti-EJ | IgG | Lineblot*** |
| anti-Jo-1 | IgG | Lineblot*** |
| anti-Ku | IgG | Lineblot*** |
| anti-Mi-2 | IgG | Lineblot*** |
| anti-Mi-2alpha | IgG | Lineblot*** |
| anti-Mi-2beta | IgG | Lineblot*** |
| anti-OJ | IgG | Lineblot*** |
| anti-PL-12 | IgG | Lineblot*** |
| anti-PL-7 | IgG | Lineblot*** |
| anti-PM-Scl | IgG | Lineblot*** |
| anti-SRP | IgG | Lineblot*** |
| anti-Mi-2alpha | IgG | Westernblot *** |
| anti-Mi-2beta | IgG | Westernblot *** |

*** not performed in-house

This document is only valid in combination with associated Quality Assessment Report.

Date of evaluation: May 10, 2022

Dr. Monika Probst
Quality Assessment Coordinator

Dr. Wolfgang Schlumberger
Member of the Advisory Board